AirSculpt Technologies (AIRS) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined 8.4% year-over-year to $51.0 million, with a net loss of $3.2 million versus net income of $1.8 million in Q2 2023, reflecting weaker demand in the aesthetics and high-end retail sectors.

• Adjusted EBITDA for Q2 2024 was $6.9 million (13.5% margin), down from $14.6 million (26.2% margin) in Q2 2023.

• CFO Dennis Dean was appointed Interim CEO following the resignation of Todd Magazine, with a search for a permanent CEO underway.

• Over 60,000 procedures have been completed since 2012, leveraging proprietary technology and a large addressable market.

• De novo centers opened in 2023 outperformed expectations, supporting future growth strategy despite macro challenges.

Financial highlights

• Q2 2024 revenue was $51.0 million (down 8.4% year-over-year); H1 2024 revenue was $98.6 million (down 2.8%).

• Q2 2024 net loss was $3.2 million; H1 2024 net income was $2.8 million.

• Adjusted net income for Q2 2024 was $5.1 million, or $0.09 per diluted share, excluding $4.9 million in equity-based compensation and $4.1 million in severance costs.

• Cash and cash equivalents at June 30, 2024 were $9.9 million, with $5.0 million available on the revolving credit facility.

• Gross debt outstanding was $71.8 million; long-term debt, net, was $67.5 million; leverage ratio at 1.81x.

• Cash flow from operations for the first six months was $6.8 million, down from $18.5 million year-over-year.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $180–$190 million; Adjusted EBITDA guidance set at $23–$28 million.

• Modest improvements expected in Q4 due to easier comparatives; continued headwinds anticipated in Q3.

• Management targets a return to 30% EBITDA margin as same-store growth and new center rollouts resume.

• Adjusted EBITDA to cash flow from operations conversion ratio projected at approximately 50%.

• Company believes cash from operations and available credit will be sufficient for at least the next 12 months, but notes risk of covenant breaches if revenue trends deteriorate.